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Abstracts / International Journal of Surgery 12 (2014) S13eS117S46resection for metastatic GIST, with relation to the recently proposed pre-
treatment classiﬁcation by Cananzi et al.
Methods: A retrospective case note analysis was performed. Pre-treatment
disease extent was classiﬁed as per Cananzi et al: type I-II non-metastatic,
resectable disease; III metastatic (synchronous) resectable disease; IV
unresectable disease. The primary outcome was 5-year survival; secondary
outcomes were disease free intervals and treatment practices.
Results: Twelve patients underwent liver resection for metastatic GISTs.
Pre-treatment, patients were classiﬁed as: type I in 3; type II in 5; type III in
2; type IV in 2. Five-year survival was 100%, 60%, 50% and 100% respec-
tively. Type I to III patients were treated with surgical resection only. Type
IV disease was downstaged with neo-adjuvant TKIs prior to resection. The
disease free interval was 73, 28, 28 and 53 months respectively (mean 36
months).
Conclusions: Neo-adjuvant TKIs therapy for metastatic GIST has a
potentially signiﬁcant role in improving 5-year survival and disease free
intervals.
0445: A CLOSED LOOP AUDIT DEMONSTRATES GREAT IMPROVEMENT
IN ACUTE PANCREATITIS CARE
Peter Davies*, Hareth Bader, Chris Battersby, Debashish Maitra. St Helens
and Knowsley NHS Trust, Merseyside, UK.
Introduction: The British Society of Gastroenterologists (BSG) updated
guidelinesonthemanagementofacutepancreatitis in2005. Thisaudit aimed
to improve acute pancreatitis care in accordance with those guidelines.
Methods: An initial audit of all 39 patients with acute pancreatitis in
October-December 2011 was undertaken. Improvements were made
through arranging group teaching for junior doctors, extra cholecystec-
tomy lists, a 7-days per week ultrasound service (5-days previously) and
combined microbiology and surgical ward rounds. Liaison with gastroen-
terologists improved ERCP availability. A retrospective re-audit was un-
dertaken of all 50 patients in February-March 2013 to complete the audit
cycle.
Results: Modiﬁed Glasgow Score was completed in 98% of re-audit cases
(85% previously). Antibiotic prescription was considered appropriate in
90% (47%). Gallstone pancreatitis was managed by cholecystectomy, either
as an inpatient or within two weeks, in 77% (10%). Ultrasound was per-
formed within 24 hours of admission in 66% (28%), ERCP was delayed in 2%
(5%) and overall mortality was 8% (10%).
Conclusions: Acute pancreatitis care was improved following several
changes. Current care follows recommended guidelines but there is room
for improvement, notably in improving ultrasound access and managing
gallstone pancreatitis.
0502: POST OPERATIVE SURGICAL DRAINS AFTER PANCREATICODUO-
DENECTOMY: SINGLE VERSUS DUAL DRAINAGE
Jamal Ghaddar*, William Paxton, Chris Briggs, Somaiah Aroori. Derriford
Hospital, Plymouth, UK.
Introduction: The placement of one or more abdominal drains after
pancreaticoduodenectomy is common practice with the rationale that this
facilitates early diagnosis of complications.
Increasing evidence suggests that drainage after abdominal surgeries may
be unnecessary.
Our aim was to evaluate the outcomes following the use of one drain
versus two drains following pancreaticoduodenectomy.
Methods: We retrospectively reviewed 182 patients chosen at random out
of a pool of 260 patients who had a pancreaticoduodenectomy between
2006 and 2013.
Patients were subdivided into two groups; those with one drain (group 1)
and patients with two drains (group 2). Data was then analysed according
to demographic factors such as age/gender and peri-operative factors such
as type of pancreatic anastomosis, date of drain removal, complications,
means used to diagnose and treat complications, length of stay, clinical
details, cancer origin and histology reports.
Results: There were 37 patients in group1 and 145 patients in group2. The
length of hospital stay was signiﬁcantly shorter in group 1 (13.16 vs 15.39
days, P<0.05). There was no statistical difference in the rate of overall
complications, intervention or re-admission in both groups.
Conclusions: The use of one drain after pancreaticoduodencetomy may
facilitate earlier discharge without increasing morbidity, mortality, re-
admission and intervention rate.0728: ROUTINE COAGULATION SCREENING IS UNNECESSARY PRIOR TO
ERCP IN NON-JAUNDICED PATIENTS; A MULTI-CENTRE STUDY
Sarah Walker*,2, Katie Mellor 2, Jonny Nicholls 1, Richard Egan 1,
Michael Stechman 1. 1University Hospital of Wales, Cardiff, UK; 2Princess of
Wales Hospital, Bridgend, UK.
Introduction: Guidelines suggest performing coagulation screening prior
to endoscopic retrograde cholangiopancreatography (ERCP). We
hypothesise that coagulation is rarely deranged in the absence of
biochemical jaundice.
Methods: All ERCP procedures performed at two centres during a 16
month period were assessed. For each patient demographic data, pre-
procedure bilirubin and prothrombin time (PT), diagnosis and bleeding
complications were recorded. Exclusion criteria were; incomplete records,
anti-coagulation therapy or inherited coagulopathy.
Results: The cohort was divided into jaundiced (n¼419) and non-jaun-
diced (n¼374) groups for analysis. Seven per cent (n¼28) of jaundiced
patients had a signiﬁcantly prolonged PT (>16.8 seconds ¼ INR of 1.5).
One non-jaundiced patient had signiﬁcantly prolonged PT, whilst 5.9 per
cent (n¼22) had a mildly raised PT (above normal range); none of these
had bleeding complications. A signiﬁcant difference in PT between groups
was seen (mean ±SD 13.0 ±6.3 vs. 11.0 ±1.2 seconds; p<0.001 t-test). The
diagnosis, ERCP procedures, and bleeding complications were equivalent
between groups and centres. The approximate cost of coagulation tests in
the non-jaundiced cohort was £7,500.
Conclusions: Patients with normal bilirubin levels rarely have deranged
coagulation suggestive of acquired coagulopathy. A negative bleeding
history and normal liver function tests makes coagulation screening an
unnecessary and expensive investigation.
0801: FITNESS TO DRIVE ADVICE AFTER ELECTIVE LAPAROSCOPIC CHO-
LECYSTECTOMY (ELC) e WHOSE RESPONSIBILITY IS IT? A SURVEY OF
CAR INSURANCE COMPANIES
Michael Courtney*, Bussa Gopinath, Duncan Light, Milind Rao. University
Hospital of North Tees, Stockton-on-Tees, UK.
Introduction: Easily accessible online advice regarding return to driving
following ELC is inconsistent. Driving too soon is unsafe and risks inva-
lidating a patient's car insurance; hence patients are often advised to
check their own insurance company's policy. This study aimed to review
UK insurance companies' advice regarding return to driving following
ELC.
Methods: An online search identiﬁed 126 car insurers; each was emailed
asking when the policyholder can return to driving following ELC, and
advice as to how he/she would know they were ﬁt to drive.
Results: 26 companies were not contactable online so excluded. Of the
remaining 100 companies, 62 responded: 61% stated their regulations, 39%
would not communicate without a conﬁrmed policy. All companies of-
fering information stated that a doctor must determine the policyholder's
ﬁtness to drive, or timescale in which they cannot. 1 stated that the poli-
cyholder needed to be able to perform an emergency stop, the rest did not
comment.
Conclusions: Insurance companies place the responsibility of determining
ﬁtness to return to driving with the patient's doctors. It is the doctor's duty
to ensure that patients have access to this information, and that infor-
mation is documented. If publically available information is to be utilised,
there is a need for standardisation.
0843: HEPATIC TRANSARTERIAL CHEMOEMBOLISATION IN EAST
LANCASHIRE: ACHIEVING INTERNATIONAL STANDARDS
Kenan Kursumovic*, Sam Byott, Ambareen Kausar, David Chang,
Neil Wilde, Duncan Gavan. Royal Blackburn Hospital, Blackburn, UK.
Introduction: Hepatic Transarterial Chemoembolisation (TACE) for non-
resectable Hepatocellular carcinoma (HCC) therapy exploits the prefer-
ential blood supply from the hepatic artery for delivery of antitumour
therapy. It is also used for other primary or metastatic liver malignancies.
We enacted a comprehensive review of the TACE service at a district
general hospital in East Lancashire, United Kingdom with a focus on pa-
tient selection, complications and survival rates.
Methods: A retrospective review was performed from 2007 to 2012,
against clinical practice guidelines published by CIRSE (2012) and SIR
(2012).
